Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
841-860 of 2,251 trials

Cytomegalovirus in Pregnancy: Valacyclovir Study

We are comparing the effectiveness and safety of valacyclovir for treating primary cytomegalovirus infection in pregnant women. The study looks at how different doses may impact treatment outcomes and safety.

CMV Infection6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Melanoma Treatment: LTX-315 and Pembrolizumab

We are studying a new treatment combination for patients with resectable stage III-IV melanoma. The goal is to see how well it shrinks tumors and affects overall health and quality of life.

Stage III Malignant Melanoma≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesDermatologyOncology

Colorectal Cancer: PD L 506 Oral Medication Study

We are investigating the safety of a new oral medication for patients with colorectal cancer and healthy volunteers. The study also looks at whether urine tests can help in diagnosing colorectal cancer.

Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

C3 Glomerulopathy and ICGN: OMS906 Study

We are testing a new drug called OMS906 in patients with C3 Glomerulopathy or Idiopathic Immune Complex-Mediated Glomerulonephritis. The study aims to evaluate the safety and early effects of this treatment on kidney function.

Immune Complex Glomerulonephritis6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesNephrology

Thyroid Eye Disease: Lu AG22515 Treatment

We are investigating the effects of Lu AG22515 on eye bulging in adults with moderate-to-severe Thyroid Eye Disease. This study aims to see if it can improve symptoms related to this condition.

Thyroid Eye Disease1-2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Gastrointestinal Cancers: MK-2870 Treatment Study

We are testing the safety and effectiveness of MK-2870, alone or with other cancer treatments, for people with gastrointestinal cancers. This study aims to see how well it works in reducing tumors and improving patient outcomes.

Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, and Biliary Tract Cancer6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Acute Progressive Stroke: Norepinephrine Treatment

We are studying whether adding norepinephrine to standard care helps improve recovery in patients with acute progressive perforating artery stroke. The goal is to see if this combination leads to better functional outcomes and reduces complications.

Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Pancreatic Cancer: Neoadjuvant Triple Treatment Study

We are exploring a new combination of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer. The goal is to see if this treatment improves survival and surgical outcomes.

Pancreatic CancerBorderline Resectable Pancreatic Cancer (BRPC)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Progressive Supranuclear Palsy: 18F-PI-2620 PET Imaging Study

We are investigating a new imaging tool to help identify and understand progressive supranuclear palsy in patients. This study may improve diagnosis and treatment options for this rare neurological condition.

Parkinson's DiseaseProgressive Supranuclear Palsy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

Vulvar Cancer: Chemoradiation Study

We are investigating if chemoradiation alone is a safe alternative to surgery for early-stage vulvar cancer patients with lymph node involvement. The study also evaluates the side effects of this treatment over time.

Vulvar Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Metastatic Colorectal and Gastroesophageal Cancer: Trifluridine/Tipiracil Study

We are studying the safety of Trifluridine/tipiracil as a new chemotherapy for patients with metastatic colorectal or gastroesophageal cancer who have a specific genetic deficiency. This trial aims to see if it can be a safer alternative to traditional treatments.

Metastatic Colon or Rectal Cancer with DPD Deficiency1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Advanced Non-Small Cell Lung Cancer: New Immunotherapy Combinations

We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Ovarian Stimulation Methods for Embryo Accumulation

We are comparing two approaches to ovarian stimulation in patients preparing for embryo testing. The goal is to see if one method produces more healthy embryos than the other.

Female InfertilityMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Sedation in Preterm Infants: Dexmedetomidine vs. Midazolam

We are comparing two sedation methods for very preterm infants on mechanical ventilation to see which one helps with extubation time and overall safety. This study will help us understand the best approach for sedation in these vulnerable patients.

Infant Sedation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPediatrics

Triple-Negative Early Breast Cancer: Sacituzumab Govitecan with or without Pembrolizumab

We are comparing two treatment options for low-risk, triple-negative early breast cancer to see which is more effective. The study also evaluates how these treatments affect patients' quality of life.

Triple-Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Epidermolysis Bullosa Simplex: Apremilast Study

We are investigating whether apremilast can improve symptoms in patients over 6 years old with epidermolysis bullosa simplex. The study will also look at the safety of the treatment and how it affects quality of life.

Epidermolysis Bullosa Simplex3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyRheumatology

Ulcerative Colitis and Crohn’s Disease: Vedolizumab for Kids

We are studying the long-term safety of vedolizumab in children with ulcerative colitis or Crohn’s disease. The trial also looks at how this treatment affects their quality of life and related health events.

Ulcerative ColitisCrohn's Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Refractory Focal Onset Epilepsy: BHV-7000 Safety Study

We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.

Focal Epilepsy1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study

We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.

Familial Chylomicronemia Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyHematology

Diabetic Kidney Disease: Hyperpolarized MRI Study

We are investigating a new MRI technique to see if it can help classify the progression of diabetic kidney disease. This study aims to improve understanding of kidney function and metabolism in affected individuals.

Diabetic Kidney Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyNephrology